Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients

NCT02227576 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT02227576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02227576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Terminated
Start date
July 10, 2014
Completion date
December 14, 2017
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, thrombocytopenia